A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review

Selective rearranged during transfection (RET) tyrosine kinase inhibitor, pralsetinib, demonstrated clinical efficacy and was well tolerated in lung and thyroid cancers with RET gene mutations or fusions in clinical trials. While the latter focused on the risk of pneumonitis, there is a lack of data...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	François Poumeaud, Marion Jaffrelot, Carlos Gomez-Roca, Iphigénie Korakis, Giulia Leonardi, Marine Joly, Julien Mazières, Rosine Guimbaud, Nadim Fares, Emily Alouani
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2024-07-01
סדרה:	Frontiers in Medicine
נושאים:	pralsetinib RET inhibitor infection JAK/STAT case report
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fmed.2024.1402902/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!